HRP20110148T1 - Koncentrirane otopine metotreksata - Google Patents
Koncentrirane otopine metotreksata Download PDFInfo
- Publication number
- HRP20110148T1 HRP20110148T1 HR20110148T HRP20110148T HRP20110148T1 HR P20110148 T1 HRP20110148 T1 HR P20110148T1 HR 20110148 T HR20110148 T HR 20110148T HR P20110148 T HRP20110148 T HR P20110148T HR P20110148 T1 HRP20110148 T1 HR P20110148T1
- Authority
- HR
- Croatia
- Prior art keywords
- methotrexate
- accordance
- intended
- use according
- disease
- Prior art date
Links
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 title claims abstract 28
- 229960000485 methotrexate Drugs 0.000 title claims abstract 28
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract 7
- 239000003814 drug Substances 0.000 claims abstract 7
- 230000002757 inflammatory effect Effects 0.000 claims abstract 7
- 239000002904 solvent Substances 0.000 claims abstract 6
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 238000002347 injection Methods 0.000 claims 8
- 239000007924 injection Substances 0.000 claims 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 6
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 4
- 229940090047 auto-injector Drugs 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000027932 Collagen disease Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 239000003708 ampul Substances 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000011521 glass Substances 0.000 claims 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 239000003755 preservative agent Substances 0.000 claims 2
- 230000002335 preservative effect Effects 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 239000008215 water for injection Substances 0.000 claims 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicinal Preparation (AREA)
Abstract
Upotreba metotreksata u proizvodnji medikamenta kojeg treba primijeniti supkutano, kod liječenja upalnih autoimunih bolesti, naznačena time što metotreksat se nalazi u farmaceutski prihvatljivom otapalu, u koncentraciji od otprilike 50 mg/ml. Patent sadrži još 27 patentnih zahtjeva.
Claims (28)
1. Upotreba metotreksata u proizvodnji medikamenta kojeg treba primijeniti supkutano, kod liječenja upalnih autoimunih bolesti, naznačena time što metotreksat se nalazi u farmaceutski prihvatljivom otapalu, u koncentraciji od otprilike 50 mg/ml.
2. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što farmaceutski prihvatljivo otapalo se bira između vode, vode za injekcije, vode koja sadrži aditive za izotonizaciju i otopine natrijevog klorida, osobito izotonične otopine natrijevog klorida.
3. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što upalnu autoimunu bolest se bira između reumatoidnog artritisa, juvenilnih artritisa, vaskulitisa, kolagenoza, Crohnove bolesti, ulceroznog kolitisa, bronhijalne astme, Alzheimerove bolesti, multiple skleroze, Behtjerevljeve bolesti, artroza zglobova ili psorijaze.
4. Upotreba u skladu s patentnim zahtjevom 3, naznačena time što upalna autoimuna bolest je reumatoidni artritis, osobito juvenilni reumatoidni artritis.
5. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što medikament se nalazi u obliku pogodnom za samoprimjenu od strane pacijenta.
6. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što medikament se nalazi u uređaju za injiciranje za jednokratnu primjenu.
7. Upotreba u skladu s patentnim zahtjevom 6, naznačena time što uređaj za injiciranje je tvornički priređena šprica.
8. Upotreba u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time što medikament se nalazi u spremniku za skladištenje.
9. Upotreba u skladu s patentnim zahtjevom 8, naznačena time što medikament dodatno sadrži konzervans.
10. Upotreba u skladu s bilo kojim od patentnih zahtjeva 8 ili 9, naznačena time što spremnik za skladištenje je injekcijska boca, bočica, vreća, staklena ampula ili karpula.
11. Upotreba u skladu s patentnim zahtjevom 10, naznačen time što spremnik za skladištenje je karpula i što navedena karpula je pogodna za primjenu medikamenta pomoću uređaja za injiciranje, osobito autoinjektora.
12. Upotreba u skladu s patentnim zahtjevom 11, naznačena time što karpula i autoinjektor su priređeni na takav način da omogućuju višestruku primjenu pojedinačnih doza.
13. Upotreba u skladu s patentnim zahtjevom 7, naznačena time što tvornički priređena šprica sadrži dozu od 5 do 40 mg, osobito 5,0, 7,5, 10,0, 12,5, 15,0, 17,5, 20,0, 22,5, 25,0, 27,5, 30,0, 32,5, 35,0, 37,5 ili 40,0 mg, metotreksata.
14. Upotreba u skladu s bilo kojim od patentnih zahtjeva 7 ili 13, naznačena time što tvornički priređena šprica je konstruirana na takav način da omogućuje samoprimjenu od strane pacijenta s ograničenom finom motorikom.
15. Metotreksat namijenjen upotrebi liječenju upalnih autoimunih bolesti, naznačen time što metotreksat treba primijeniti supkutano i što se metotreksat nalazi u farmaceutski prihvatljivom otapalu, u koncentraciji od otprilike 50 mg/ml.
16. Metotreksat namijenjen upotrebi u skladu s patentnim zahtjevom 15, naznačen time što farmaceutski prihvatljivo otapalo se bira između vode, vode za injekcije, vode koja sadrži aditive za izotonizaciju i otopine natrijevog klorida, osobito izotonične otopine natrijevog klorida.
17. Metotreksat namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 15 ili 16, naznačen time što upalnu autoimunu bolest se bira između reumatoidnog artritisa, juvenilnih artritisa, vaskulitisa, kolagenoza, Crohnove bolesti, ulceroznog kolitisa, bronhijalne astme, Alzheimerove bolesti, multiple skleroze, Behtjerevljeve bolesti, artroza zglobova ili psorijaze.
18. Metotreksat namijenjen upotrebi u skladu s patentnim zahtjevom 17, naznačen time što upalna autoimuna bolest je reumatoidni artritis, osobito juvenilni reumatoidni artritis.
19. Metotreksat namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 15 do 18, naznačen time što metotreksat se nalazi u obliku pogodnom za samoprimjenu od strane pacijenta.
20. Metotreksat namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 15 do 19, naznačen time što metotreksat se nalazi u uređaju za injiciranje namijenjen za jednokratnu primjenu.
21. Metotreksat namijenjen upotrebi u skladu s patentnim zahtjevom 20, naznačen time što uređaj za injiciranje je tvornički priređena šprica.
22. Metotreksat namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 15 do 19, naznačen time što metotreksat se nalazi u spremniku za skladištenje.
23. Metotreksat namijenjen upotrebi u skladu s patentnim zahtjevom 22, naznačen time što otapalo koje sadrži metotreksat dodatno sadrži konzervans.
24. Metotreksat namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 22 ili 23, naznačen time što spremnik za skladištenje je injekcijska boca, bočica, vreća, staklena ampula ili karpula.
25. Metotreksat namijenjen upotrebi u skladu s patentnim zahtjevom 24, naznačen time što spremnik za skladištenje je karpula i što navedena karpula je pogodna za primjenu metotreksata pomoću uređaja za injiciranje, osobito autoinjektora.
26. Metotreksat namijenjen upotrebi u skladu s patentnim zahtjevom 25, naznačen time što karpula i autoinjektor su priređeni na takav način da omogućuju višestruku primjenu pojedinačnih doza.
27. Metotreksat namijenjen upotrebi u skladu s patentnim zahtjevom 21, naznačen time što tvornički priređena šprica sadrži dozu od 5 do 40 mg, osobito 5,0, 7,5, 10,0, 12,5, 15,0, 17,5, 20,0, 22,5, 25,0, 27,5, 30,0, 32,5, 35,0, 37,5 ili 40,0 mg, metotreksata.
28. Metotreksat namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 21 ili 27, naznačen time što tvornički priređena šprica je konstruirana na takav način da omogućuje samoprimjenu od strane pacijenta s ograničenom finom motorikom.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006033837A DE102006033837A1 (de) | 2006-07-21 | 2006-07-21 | Konzentrierte Methotrexat-Lösungen |
| PCT/EP2007/006491 WO2008009476A2 (de) | 2006-07-21 | 2007-07-20 | Konzentrierte methotrexat-lösungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110148T1 true HRP20110148T1 (hr) | 2011-03-31 |
Family
ID=38640096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110148T HRP20110148T1 (hr) | 2006-07-21 | 2011-02-28 | Koncentrirane otopine metotreksata |
Country Status (22)
| Country | Link |
|---|---|
| US (7) | US8664231B2 (hr) |
| EP (2) | EP2046332B1 (hr) |
| JP (1) | JP5683810B2 (hr) |
| KR (1) | KR101260554B1 (hr) |
| AT (2) | AT14872U1 (hr) |
| AU (1) | AU2007276387B2 (hr) |
| BR (1) | BRPI0715433A2 (hr) |
| CA (2) | CA2869671A1 (hr) |
| CY (1) | CY1111159T1 (hr) |
| DE (3) | DE102006033837A1 (hr) |
| DK (1) | DK2046332T3 (hr) |
| ES (1) | ES2355399T3 (hr) |
| HR (1) | HRP20110148T1 (hr) |
| ME (1) | ME01940B (hr) |
| MX (1) | MX2009000812A (hr) |
| PL (1) | PL2046332T3 (hr) |
| PT (1) | PT2046332E (hr) |
| RS (1) | RS51688B (hr) |
| RU (1) | RU2403044C1 (hr) |
| SI (1) | SI2046332T1 (hr) |
| UA (1) | UA95488C2 (hr) |
| WO (1) | WO2008009476A2 (hr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2314182T3 (es) | 2002-02-11 | 2009-03-16 | Antares Pharma, Inc. | Inyector intradermico. |
| EP1850892B2 (en) | 2005-01-24 | 2023-04-19 | Antares Pharma, Inc. | Prefilled needle assisted syringe jet injector |
| WO2007131025A1 (en) | 2006-05-03 | 2007-11-15 | Antares Pharma, Inc. | Injector with adjustable dosing |
| WO2007131013A1 (en) | 2006-05-03 | 2007-11-15 | Antares Pharma, Inc. | Two-stage reconstituting injector |
| DE102006033837A1 (de) | 2006-07-21 | 2008-01-31 | Medac Gesellschaft für klinische Spezialpräparate m.b.H | Konzentrierte Methotrexat-Lösungen |
| AU2007323541B2 (en) * | 2006-11-21 | 2012-01-19 | Kalobios Pharmaceuticals, Inc. | Methods of treating chronic inflammatory diseases using a GM-CSF antagonist |
| JP5731829B2 (ja) | 2008-03-10 | 2015-06-10 | アンタレス・ファーマ・インコーポレーテッド | 注射器安全装置 |
| AU2009279719B2 (en) | 2008-08-05 | 2015-07-23 | Antares Pharma, Inc. | Multiple dosage injector |
| JP5732039B2 (ja) * | 2009-03-20 | 2015-06-10 | アンタレス・ファーマ・インコーポレーテッド | 危険有害性薬剤の注入システム |
| US9770414B2 (en) | 2010-05-13 | 2017-09-26 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent |
| US8496619B2 (en) | 2011-07-15 | 2013-07-30 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
| US9220660B2 (en) | 2011-07-15 | 2015-12-29 | Antares Pharma, Inc. | Liquid-transfer adapter beveled spike |
| GB201200192D0 (en) * | 2012-01-06 | 2012-02-22 | Rosemont Pharmaceuticals Ltd | Methotrexate composition |
| DK2822618T3 (da) | 2012-03-06 | 2024-01-22 | Antares Pharma Inc | Forfyldt nål med brudkraftfunktion |
| EP4186545A1 (en) | 2012-04-06 | 2023-05-31 | Antares Pharma, Inc. | Needle assisted jet injection administration of testosterone compositions |
| US9364610B2 (en) | 2012-05-07 | 2016-06-14 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
| CN104936639A (zh) * | 2013-01-29 | 2015-09-23 | 赛诺菲-安万特德国有限公司 | 电子模块和药物输送装置 |
| EP4349383A2 (en) | 2013-02-11 | 2024-04-10 | Antares Pharma, Inc. | Needle assisted jet injection device having reduced trigger force |
| JP6030803B2 (ja) | 2013-03-11 | 2016-11-24 | アンタレス・ファーマ・インコーポレーテッド | ピニオンシステムを有する用量注射器 |
| WO2014165136A1 (en) | 2013-03-12 | 2014-10-09 | Antares Pharma, Inc. | Constant volume prefilled syringes and kits thereof |
| WO2015147018A1 (ja) * | 2014-03-28 | 2015-10-01 | テルモ株式会社 | 炎症性自己免疫疾患治療用の注射用水性製剤 |
| US20150297600A1 (en) * | 2014-04-16 | 2015-10-22 | Antares Pharma, Inc. | Method Of Achieving Increased Systemic Availability of Methotrexate |
| WO2015183213A1 (en) | 2014-05-28 | 2015-12-03 | Onko İlaç Sanayi̇ Ve Ti̇caret A. Ş. | Pharmaceutical dosage forms containing n-[4-[[(2,4-diamino-6-pteridinyl)methyl] methylamino] benzoyl]-l- glutamic acid and n-[4-[[(2-amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-l-glutamic acid |
| JP2017066073A (ja) * | 2015-09-29 | 2017-04-06 | テルモ株式会社 | 炎症性自己免疫疾患治療用の注射用水性製剤およびその保存方法 |
| KR102095284B1 (ko) | 2017-05-11 | 2020-04-01 | (주)케어젠 | 메토트렉세이트와 펩타이드의 결합체 |
| WO2020044114A2 (en) * | 2018-08-29 | 2020-03-05 | Ftf Pharma Private Limited | Methotrexate pharmaceutical composition |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4357971A (en) * | 1980-09-19 | 1982-11-09 | Cyberon Corporation | Syringe gauging, loading and injection apparatus |
| US5279586A (en) * | 1992-02-04 | 1994-01-18 | Becton, Dickinson And Company | Reusable medication delivery pen |
| JPH08505543A (ja) * | 1992-11-19 | 1996-06-18 | テブロ ソシエテ アノニム | 予充填注射器用の使い捨て自動注射装置 |
| US5593671A (en) | 1994-07-01 | 1997-01-14 | American Cyanamid Company | Method of attenuating lung capillary leak in a mammal |
| US5542934A (en) * | 1995-06-02 | 1996-08-06 | Silver; Richard M. | Multiple carpule hypodermic syringe |
| US6544504B1 (en) | 1999-07-28 | 2003-04-08 | Schering Corporation | Combined use of interleukin 10 and methotrexate for immuno-modulatory therapy |
| JP2004536786A (ja) * | 2001-03-02 | 2004-12-09 | メディミューン，インコーポレイテッド | インテグリンαｖβ３拮抗薬を他の予防薬もしくは治療薬と組み合わせて投与することによる炎症性疾患または自己免疫疾患の予防または治療方法 |
| US20040176381A1 (en) * | 2003-03-06 | 2004-09-09 | Walsh Michael J. | Methotrexate compliance packaging |
| US20050153969A1 (en) * | 2004-01-13 | 2005-07-14 | Iomed, Inc. | Methods for treating neoplastic, angiogenic, fibroblastic, and/or immunosuppressive ocular irregularities via administration of methotrexate based medicaments, and ocular iontophoretic devices for delivering methotrexate based medicament |
| DE102006033837A1 (de) * | 2006-07-21 | 2008-01-31 | Medac Gesellschaft für klinische Spezialpräparate m.b.H | Konzentrierte Methotrexat-Lösungen |
-
2006
- 2006-07-21 DE DE102006033837A patent/DE102006033837A1/de active Pending
-
2007
- 2007-07-20 ME MEP-2011-207A patent/ME01940B/me unknown
- 2007-07-20 RU RU2009106053/15A patent/RU2403044C1/ru active
- 2007-07-20 SI SI200730475T patent/SI2046332T1/sl unknown
- 2007-07-20 BR BRPI0715433-0A patent/BRPI0715433A2/pt not_active Application Discontinuation
- 2007-07-20 DE DE502007005972T patent/DE502007005972D1/de active Active
- 2007-07-20 EP EP07786239A patent/EP2046332B1/de active Active
- 2007-07-20 PT PT07786239T patent/PT2046332E/pt unknown
- 2007-07-20 JP JP2009521153A patent/JP5683810B2/ja active Active
- 2007-07-20 DE DE202007019703.9U patent/DE202007019703U1/de not_active Expired - Lifetime
- 2007-07-20 CA CA2869671A patent/CA2869671A1/en not_active Abandoned
- 2007-07-20 MX MX2009000812A patent/MX2009000812A/es active IP Right Grant
- 2007-07-20 ES ES07786239T patent/ES2355399T3/es active Active
- 2007-07-20 DK DK07786239.9T patent/DK2046332T3/da active
- 2007-07-20 RS RS20110010A patent/RS51688B/en unknown
- 2007-07-20 CA CA2659662A patent/CA2659662C/en active Active
- 2007-07-20 KR KR1020097003655A patent/KR101260554B1/ko active IP Right Grant
- 2007-07-20 US US12/374,528 patent/US8664231B2/en active Active
- 2007-07-20 AT ATGM50122/2015U patent/AT14872U1/de not_active IP Right Cessation
- 2007-07-20 PL PL07786239T patent/PL2046332T3/pl unknown
- 2007-07-20 EP EP10194145A patent/EP2292235A3/de not_active Withdrawn
- 2007-07-20 UA UAA200901346A patent/UA95488C2/ru unknown
- 2007-07-20 AU AU2007276387A patent/AU2007276387B2/en active Active
- 2007-07-20 AT AT07786239T patent/ATE491455T1/de active
- 2007-07-20 WO PCT/EP2007/006491 patent/WO2008009476A2/de active Application Filing
-
2011
- 2011-02-03 CY CY20111100118T patent/CY1111159T1/el unknown
- 2011-02-28 HR HR20110148T patent/HRP20110148T1/hr unknown
-
2014
- 2014-02-07 US US14/175,357 patent/US20140155405A1/en not_active Abandoned
- 2014-03-03 US US14/195,117 patent/US20140179703A1/en not_active Abandoned
-
2015
- 2015-03-02 US US14/635,542 patent/US20150164902A1/en not_active Abandoned
-
2017
- 2017-05-11 US US15/592,882 patent/US20170246172A1/en not_active Abandoned
-
2018
- 2018-10-05 US US16/152,463 patent/US10610531B2/en active Active
-
2020
- 2020-02-25 US US16/800,584 patent/US11944629B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110148T1 (hr) | Koncentrirane otopine metotreksata | |
| HRP20171939T1 (hr) | Formulacija protutijela i režimi terapije | |
| HRP20191923T1 (hr) | Postupci i sastavi za isporuku arilsulfataze a u cns | |
| HRP20170270T1 (hr) | Metoda davanja plućnog surfaktanta | |
| JP2010511596A5 (hr) | ||
| IL309340A (en) | Dosing regimen for missing doses of paliperidone long-acting injectable esters | |
| RU2016139373A (ru) | Растворы бупренорфина с замедленным высвобождением | |
| RU2011121612A (ru) | Инъекционная композиция полидезоксирибонуклеотидов для лечения костно-суставных заболеваний | |
| RU2010129824A (ru) | Новый функционально активный, высокоочищенный, стабильный конъюгат интерферона альфа с полиэтиленгликолем, представленный одним позиционным изомером пэг-nаh-ифн, с уменьшенной иммуногенностью, с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе | |
| WO2007022609B1 (en) | Pharmaceutical composition of morphine in ready-to-use injectable solution form and single dosage form of morphine for epidural or intrathecal administration | |
| CN102266549A (zh) | 一种含有阿加曲班的注射用制剂 | |
| CA2496121A1 (en) | Stable formulations of hyaluronic acid for use in the therapeutic treatment of arthropathy | |
| RU2021118782A (ru) | Способ лечения сосудистых заболеваний | |
| JP4707327B2 (ja) | ポリペプタイド類の吸着防止剤 | |
| Kwon et al. | Drug Conversion from a Mixture of Fentanyl and Bupivacaine to Morphine in Intrathecal Drug Administration Pump: A Case Report | |
| KR20140050593A (ko) | 히알루론산 또는 히알루론산염을 포함하는 수용액 | |
| KR20140024863A (ko) | 히알루론산 또는 히알루론산염을 포함하는 수용액 | |
| CN105061565A (zh) | 干扰素调节因子5抑制多肽及其应用 | |
| UA55302U (uk) | Стабільна фармацевтична композиція на основі інтерферону-альфа 2b | |
| PT1683518E (pt) | Formulação farmacêutica de formoterol e propilenoglicol |